All AbMole products are for research use only, cannot be used for human consumption.
AEE788 (NVP-AEE788) is a novel multitargeted human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. In cells, growth factor-induced EGFR and ErbB2 phosphorylation was also efficiently inhibited with IC50s of 11 and 220 nM, respectively. It efficiently inhibited growth factor-induced EGFR and ErbB2 phosphorylation in tumors for >72 h, a phenomenon correlating with the antitumor efficacy of intermittent treatment schedules. AEE788 also inhibits VEGF-induced angiogenesis in a murine implant model. It has potential as an anticancer agent targeting deregulated tumor cell proliferation as well as angiogenic parameters.
 |
Source | PLoS One (2017). Figure 4. AEE788 |
| Method | Western blot analyses | |
| Cell Lines | TGCT cell lines | |
| Concentrations | 30 nM | |
| Incubation Time | 24 h | |
| Results | Interestingly, treatment with AEE788 also led to a decreased activation of mTOR in some cell lines |
| Cell Experiment | |
|---|---|
| Cell lines | NCI-H596, BT-474, SK-BR-3, 32D/EGFR, T24, MCF-7 and MCF-7/EGFRvII cells |
| Preparation method | Endothelial Cell Proliferation Assay. To test the effects of AEE788 on serum, VEGF, EGF, and basic fibroblast growth factor (bFGF)-induced proliferation of human umbilical vein endothelial cells an endothelial cell proliferation assay, based on BrdUrd incorporation, was used as already. |
| Concentrations | 0~10µM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | mouse xenografts models NCI-H596 and DU145 tumors |
| Formulation | N-methylpyrrolidone and PEG300 1:9 (v/v) |
| Dosages | 7.5, 15, 30, 50mg/kg *3days weekly for 35 days |
| Administration | p.o. |
| Molecular Weight | 440.58 |
| Formula | C27H32N6 |
| CAS Number | 497839-62-0 |
| Solubility (25°C) | DMSO ≥ 65 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related EGFR/HER2 Products |
|---|
| Sapitinib (AZD8931)
AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively. |
| Afatinib
Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| CP-724714
CP-724714 is a potent and selective orally active HER-2 tyrosine kinase inhibitor, IC50 = 3 nM. |
| Icotinib
Icotinib (BPI-2009H) is a potent and novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC50 of 5 nM. Iconitib inhibits the proliferation of A431 and BGC-823 A549, H460 and KB cell lines with IC50s of 1, 4.06, 12.16, 16.08, 40.71 μM. |
| WZ4002
WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
